Nephroblastoma is a rare kidney cancer that affects children with 3 to 4 years of age. Occurrence of nephroblastoma in children after the age of 5 is observed rarely. This cancer, sometimes called as wilms’ tumor can also affect both kidneys together, as it affects only one kidney typically. When there are DNA errors in cells, it leads to development of cancer. Due to these errors, the cells start growing and dividing uncontrollably, which further leads to formation of a tumor. This entire process occurs in nephroblastoma of the kidney cells.
Global nephroblastoma treatment market is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2030).
Frequent regulatory approvals for new nephroblastoma treatments is expected to propel growth of the global nephroblastoma treatment market during the forecast period. Market players are focusing on approvals from regulatory authorities for new drugs. For instance, in May 2022, the U.S. Food and Drug Administration granted approval to Cue Biopharma, Inc. for its Investigational New Drug application for evaluating CUE-102 in a dose escalation and monotherapy expansion Phase 1 trial.
Moreover, market players are focusing on R&D activities for new treatments, which is also expected to augment growth of the global nephroblastoma treatment market during the forecast period. For instance, in August 2022, Children’s Oncology Group studying the combination chemotherapy and surgery effects on young patients suffering from wilms tumor revealed to be in Phase 3 trial and that the study is likely to be completed by end of the year 2023.
Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5192
Impact of COVID-19:
The outbreak of COVID-19 in China spread across over 200 countries around the world. It significantly affected the global economy. Major market activities were disrupted during the pandemic. Manufacturing plants were closed down temporarily under lockdown regulations. Moreover, as the patient burden on hospital was increasing on hospitals due to COVID-19, several medical facilities suspended non-emergency medical procedures to prevent COVID-19 infections in patients. Thus, the nephroblastoma treatment market was adversely impacted by the COVID-19 pandemic. For instance, in September 2021, the National Center for Biotechnology Information published an article as per which, the U.K. government announced postponement of routine screening for cancer in March 2020 in response to the pandemic.
High cost of nephroblastoma treatment is likely to obstruct growth of the global nephroblastoma treatment market during the forecast period. For instance, in November 2018, the American Society of Clinical Oncology published an article according to which, the cost of a full course of nephroblastoma treatment along with follow-up was US$ 1,490 to US$ 2,093, as per the Butaro Cancer Center of Excellence (BCCOE).
Major players functioning in the global nephroblastoma treatment market are Xediton Pharmaceuticals, Merck & Co., Inc., Cadila Pharmaceuticals Ltd., Recordati Rare Diseases, Amneal Pharmaceuticals LLC., Pfizer Inc., Baxter, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ireland Ltd., Cipla Inc., Alvogen, Actiza Pharmaceutical Private Limited, and Teva Pharmaceutical Industries Ltd.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/5192
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Nephroblastoma Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Nephroblastoma Treatment Industry Impact
Chapter 2 Global Nephroblastoma Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Nephroblastoma Treatment (Volume and Value) by Type
2.3 Global Nephroblastoma Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Nephroblastoma Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Nephroblastoma Treatment Market Analysis
Chapter 6 East Asia Nephroblastoma Treatment Market Analysis
Chapter 7 Europe Nephroblastoma Treatment Market Analysis
Chapter 8 South Asia Nephroblastoma Treatment Market Analysis
Chapter 9 Southeast Asia Nephroblastoma Treatment Market Analysis
Chapter 10 Middle East Nephroblastoma Treatment Market Analysis
Chapter 11 Africa Nephroblastoma Treatment Market Analysis
Chapter 12 Oceania Nephroblastoma Treatment Market Analysis
Chapter 13 South America Nephroblastoma Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Nephroblastoma Treatment Business
Chapter 15 Global Nephroblastoma Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5192
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027